These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 12102274)

  • 21. Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis.
    Cummins L; Katikireddi VS; Shankaranarayana S; Su KY; Duggan E; Videm V; Pahau H; Thomas R
    Intern Med J; 2015 Dec; 45(12):1266-73. PubMed ID: 26384029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapies for active rheumatoid arthritis after methotrexate failure.
    O'Dell JR; Mikuls TR; Taylor TH; Ahluwalia V; Brophy M; Warren SR; Lew RA; Cannella AC; Kunkel G; Phibbs CS; Anis AH; Leatherman S; Keystone E;
    N Engl J Med; 2013 Jul; 369(4):307-18. PubMed ID: 23755969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination DMARD therapy with hydroxychloroquine, sulfasalazine, and methotrexate.
    O'Dell JR
    Clin Exp Rheumatol; 1999; 17(6 Suppl 18):S53-8. PubMed ID: 10589358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.
    Möttönen T; Hannonen P; Korpela M; Nissilä M; Kautiainen H; Ilonen J; Laasonen L; Kaipiainen-Seppänen O; Franzen P; Helve T; Koski J; Gripenberg-Gahmberg M; Myllykangas-Luosujärvi R; Leirisalo-Repo M;
    Arthritis Rheum; 2002 Apr; 46(4):894-8. PubMed ID: 11953964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis].
    Gubar' EE; Bochkova AG; Bunchuk NV
    Ter Arkh; 2008; 80(5):25-30. PubMed ID: 18590110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of triple association methotrexate, sulfasalazine and hydroxychloroquine in early treatment of rheumatoid arthritis with insufficient response to methotrexate: Meta-analysis of randomized controlled trials.
    Mazouyès A; Clay M; Bernard AC; Gaudin P; Baillet A
    Joint Bone Spine; 2017 Oct; 84(5):563-570. PubMed ID: 27989589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Toxicity of anti-rheumatic drugs in a randomized clinical trial of early rheumatoid arthritis.
    van Jaarsveld CH; Jahangier ZN; Jacobs JW; Blaauw AA; van Albada-Kuipers GA; ter Borg EJ; Brus HL; Schenk Y; van Der Veen MJ; Bijlsma JW
    Rheumatology (Oxford); 2000 Dec; 39(12):1374-82. PubMed ID: 11136881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term application of disease modifying antirheumatic drugs (DMARD). A single-center, observational study of 1681 patients with rheumatoid arthritis (RA).
    Keysser M; Keysser G; Keysser C
    Z Rheumatol; 1999 Oct; 58(5):267-76. PubMed ID: 10591974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
    Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial.
    van Vollenhoven RF; Ernestam S; Geborek P; Petersson IF; Cöster L; Waltbrand E; Zickert A; Theander J; Thörner A; Hellström H; Teleman A; Dackhammar C; Akre F; Forslind K; Ljung L; Oding R; Chatzidionysiou A; Wörnert M; Bratt J
    Lancet; 2009 Aug; 374(9688):459-66. PubMed ID: 19665644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of sulphasalazine and methotrexate in the treatment of rheumatoid arthritis.
    Dougados M
    Z Rheumatol; 1998 Feb; 57(1):31-3. PubMed ID: 9566104
    [No Abstract]   [Full Text] [Related]  

  • 32. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects.
    Hurst S; Kallan MJ; Wolfe FJ; Fries JF; Albert DA
    J Rheumatol; 2002 Aug; 29(8):1639-45. PubMed ID: 12180722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
    van Halm VP; Nurmohamed MT; Twisk JW; Dijkmans BA; Voskuyl AE
    Arthritis Res Ther; 2006; 8(5):R151. PubMed ID: 16984661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis.
    Wassenberg S; Rau R
    J Rheumatol; 2003 Aug; 30(8):1891; author reply 1891-2. PubMed ID: 12913889
    [No Abstract]   [Full Text] [Related]  

  • 35. Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis and seronegative arthritis.
    Nandi P; Kingsley GH; Scott DL
    Curr Opin Rheumatol; 2008 May; 20(3):251-6. PubMed ID: 18388514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis.
    Ravindran V; Scott DL; Choy EH
    Ann Rheum Dis; 2008 Jun; 67(6):855-9. PubMed ID: 17827183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-study.
    Hissink Muller PC; Brinkman DM; Schonenberg D; Koopman-Keemink Y; Brederije IC; Bekkering WP; Kuijpers TW; van Rossum MA; van Suijlekom-Smit LW; van den Berg JM; Allaart CF; Ten Cate R
    Pediatr Rheumatol Online J; 2017 Feb; 15(1):11. PubMed ID: 28166785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Termination of disease-modifying drugs in psoriatic arthritis: study of 109 courses of treatment.
    Gómez-Vaquero C; Rodríguez-Moreno J; Ros S; Marcos R; Fiter J; Roig-Escofet D
    Br J Rheumatol; 1996 Jun; 35(6):564-7. PubMed ID: 8670578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biological vs. conventional combination treatment and work loss in early rheumatoid arthritis: a randomized trial.
    Eriksson JK; Neovius M; Bratt J; Petersson IF; van Vollenhoven RF; Geborek P; Ernestam S
    JAMA Intern Med; 2013 Aug; 173(15):1407-14. PubMed ID: 23817631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The comparative efficacy of slow-acting (basic) preparations in psoriatic arthritis].
    Burdeĭnyĭ AP; Agababova ER; Korotaeva TV; Kharamil'o LF
    Ter Arkh; 1992; 64(5):54-9. PubMed ID: 1360714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.